Inspyr Therapeutics, Inc., a biotech company, announced the appointment of Claire Thom to its board of directors.
Inspyr Therapeutics appoints Claire Thom to board of directorsStaff Writer | Westlake Village, Ca., USA | Thursday October 13, 2016 8:27AM ET
READ MOREMs. Thom has two decades of experience in the pharmaceutical industry, with responsibilities including drug development, new product planning, and marketing.
Most recently, Ms. Thom was the Senior Vice President Global Therapeutic Head for Oncology at Astellas Pharma, from 2013 through her retirement in July 2016.
In addition, she was appointed to serve on the Board of Directors for Agensys, a fully-owned subsidiary of Astellas.
Previously, Ms. Thom served as Millennium’s Senior Vice President of Portfolio Management, Drug Development Management and Strategic Business Operations.
Before Millennium, she worked with Takeda Pharmaceutical Company, where she held several positions of increasing responsibility to become the company’s Oncology Franchise Leader.
Earlier, she worked at G.D. Searle and began her career as a clinical pharmacist. Ms. Thom was awarded a Doctor of Pharmacy and a Bachelor of Pharmacy, both with honors, from the University of Illinois. ■